<div dir="ltr"><div dir="ltr"><br></div><br><div class="gmail_quote"><div dir="ltr" class="gmail_attr">On Fri, Sep 13, 2019 at 5:33 PM Heather Morrison <<a href="mailto:Heather.Morrison@uottawa.ca">Heather.Morrison@uottawa.ca</a>> wrote:<br></div><blockquote class="gmail_quote" style="margin:0px 0px 0px 0.8ex;border-left:1px solid rgb(204,204,204);padding-left:1ex">
<div>
Peter (or others).<br>
<br>
You refer to pharma companies paying tens of thousands of dollars to re-use open access works. Can you explain / provide examples? If works are free-to-read, even with All Rights Reserved copyright, pharma companies and their researchers can read and benefit
from knowledge produced to date to further knowledge at no cost.<br></div></blockquote><div><br></div><div>See <span style="color:rgb(0,0,0);font-family:Times;font-size:15px;white-space:pre-wrap"><a href="https://twitter.com/petermurrayrust/status/1172554433202458625?s=20">https://twitter.com/petermurrayrust/status/1172554433202458625?s=20</a> 6000 USD for re-use of figures from an NC Cell article in pharma promotion.
This is not "voluntary"
I have said quite enough on this. If anyone cares about price-gouging by publishers feel free to re-use my tweet under CC BY.</span></div><div><span style="color:rgb(0,0,0);font-family:Times;font-size:15px;white-space:pre-wrap">
</span></div></div><div><br></div>-- <br><div dir="ltr" class="gmail_signature"><div dir="ltr"><div><div dir="ltr"><div>"I always retain copyright in my papers, and nothing in any contract I sign with any publisher will override that fact. You should do the same".<br></div><div><br></div><div>Peter Murray-Rust<br>Reader Emeritus in Molecular Informatics<br>Unilever Centre, Dept. Of Chemistry<br>University of Cambridge<br>CB2 1EW, UK<br>+44-1223-763069</div></div></div></div></div></div>